Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 8/20 | 0.46 |
| ▸ | PARP1 | P09874 | 4/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6649511 | 0.84 | TNKS (0.61) | HTR3ATNKSPARP1APAF1CDC25B | |
| SCHEMBL6646076 | 0.83 | TNKS (0.51) | HTR3ATNKSPARP1HRH4APAF1 | |
| SCHEMBL6644067 | 0.83 | PARP1 (0.54) | HTR3ATNKSPARP1HRH4APAF1 | |
| SCHEMBL6647649 | 0.83 | HTR3A (0.46) | HTR3ATNKSPARP1HRH4APAF1 | |
| SCHEMBL6646683 | 0.83 | TNKS (0.60) | HTR3ATNKSPARP1HRH4SMN1; SMN2 | |
| SCHEMBL6646301 | 0.83 | PARP1 (0.42) | HTR3APARP1APAF1CDC25BCASP3 | |
| SCHEMBL6648503 | 0.83 | TNKS (0.43) | HTR3ATNKSPARP1HRH4SMN1; SMN2 | |
| SCHEMBL6649508 | 0.82 | SMN1; SMN2 (0.45) | HTR3ATNKSPARP1HRH4SMN1; SMN2 | |
| SCHEMBL6645672 | 0.81 | TNKS (0.49) | HTR3ATNKSPARP1HRH4SMN1; SMN2 | |
| SCHEMBL6645847 | 0.81 | HTR3A (0.44) | HTR3ATNKSPARP1HRH4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | claimed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | claimed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | HTR3A 2987/4885TNKS 121/4885PARP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.